Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


18.04.2022

1 ACS Nano
1 Acta Med Indones
1 Am J Cancer Res
1 Ann Clin Lab Sci
3 Ann Surg Oncol
1 Biochem Genet
1 Biomed Res Int
1 BJU Int
3 BMC Urol
2 Cancer Diagn Progn
3 Cancers (Basel)
1 Cell Death Discov
1 Cells
1 Clin Cancer Res
13 Clin Genitourin Cancer
1 Clin Nutr
1 Cureus
1 Curr Oncol
1 Curr Treat Options Oncol
1 Drugs Aging
9 Eur Urol Focus
1 Eur Urol Oncol
1 Expert Rev Anticancer Ther
1 Front Genet
1 Front Immunol
1 Funct Integr Genomics
1 Int J Environ Res Public Health
1 Int J Mol Sci
1 Int J Nanomedicine
1 Int J Surg Pathol
1 J Clin Lab Anal
1 J Nephrol
1 J Osteopath Med
1 J Urol
1 Lancet Oncol
2 Nat Commun
1 PLoS One
1 Proc Natl Acad Sci U S A
1 Sci Rep
2 Transl Androl Urol
2 Urol Oncol
1 Virchows Arch
3 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    ACS Nano

  1. DING K, Wang L, Zhu J, He D, et al
    Photo-Enhanced Chemotherapy Performance in Bladder Cancer Treatment via Albumin Coated AIE Aggregates.
    ACS Nano. 2022 Apr 12. doi: 10.1021/acsnano.1c10770.
    PubMed         Abstract available


    Acta Med Indones

  2. SHINWARI K, Chen Z, Liu G, Chen L, et al
    Identification of The Immune Subtype Among Muscle-invasive Bladder Cancer Patients by Multiple Datasets.
    Acta Med Indones. 2022;54:62-71.
    PubMed         Abstract available


    Am J Cancer Res

  3. LIN MH, Islam A, Liu YH, Weng CW, et al
    Antibiotic heliomycin and its water-soluble 4-aminomethylated derivative provoke cell death in T24 bladder cancer cells by targeting sirtuin 1 (SIRT1).
    Am J Cancer Res. 2022;12:1042-1055.
    PubMed         Abstract available


    Ann Clin Lab Sci

  4. OU L, Wei Z, Xu J, Li W, et al
    FAM107A as a Tumor Suppressor in Bladder Cancer Inhibits Cell Proliferation, Migration, and Invasion.
    Ann Clin Lab Sci. 2022;52:260-268.
    PubMed         Abstract available


    Ann Surg Oncol

  5. LIN TW, Lee HY, Yang SF, Li CC, et al
    ASO Visual Abstract: Perineural Invasion is a Powerful Prognostic Factor for Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy.
    Ann Surg Oncol. 2022;29:3320-3321.
    PubMed        

  6. LIN TW, Yeh HC
    ASO Author Reflections: Prognostic Significance of Perineural Invasion in Upper Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2022;29:3318-3319.
    PubMed        

  7. LIN TW, Lee HY, Yang SF, Li CC, et al
    Perineural Invasion is a Powerful Prognostic Factor for Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy.
    Ann Surg Oncol. 2022;29:3306-3317.
    PubMed         Abstract available


    Biochem Genet

  8. LI G, Wang Y, Guo XB, Zhao B, et al
    CDC42 Regulates Cell Proliferation and Apoptosis in Bladder Cancer via the IQGAP3-Mediated Ras/ERK Pathway.
    Biochem Genet. 2022 Apr 12. pii: 10.1007/s10528-022-10223.
    PubMed         Abstract available


    Biomed Res Int

  9. LI X, Liu H, Lv C, Du J, et al
    Gypenoside-Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer.
    Biomed Res Int. 2022;2022:9304552.
    PubMed         Abstract available


    BJU Int

  10. SCHUETTFORT VM, D'Andrea D, Quhal F, Mostafaei H, et al
    A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.
    BJU Int. 2022;129:182-193.
    PubMed         Abstract available


    BMC Urol

  11. YE JB, Chen Q, Zeng K, Li XB, et al
    Eosinophilic cystitis complicated with cystitis glandularis: a case report.
    BMC Urol. 2022;22:55.
    PubMed         Abstract available

  12. ABUHASANEIN S, Hansen C, Vojinovic D, Jahnson S, et al
    Computed tomography urography with corticomedullary phase can exclude urinary bladder cancer with high accuracy.
    BMC Urol. 2022;22:60.
    PubMed         Abstract available

  13. YAMAMOTO A, Kawashima A, Uemura T, Yamamichi G, et al
    Biological distinction between grades 2 and 3 with respect to intravesical recurrence in T1 high-grade bladder tumors: a retrospective study.
    BMC Urol. 2022;22:59.
    PubMed         Abstract available


    Cancer Diagn Progn

  14. WEIDLE UH, Birzele F
    Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.
    Cancer Diagn Progn. 2021;1:245-263.
    PubMed         Abstract available

  15. WATANABE K, Tamura K, Matsushita Y, Watanabe H, et al
    Significance of 5-Aminolevulinic Acid-mediated Photodynamic Diagnosis Following Standard Transurethral Resection in Non-muscle Invasive Bladder Cancer.
    Cancer Diagn Progn. 2021;1:201-205.
    PubMed         Abstract available


    Cancers (Basel)

  16. THOMAS J, Sonpavde G
    Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

  17. LU YT, Xu T, Iqbal M, Hsieh TC, et al
    FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

  18. SJODAHL G, Abrahamsson J, Bernardo C, Eriksson P, et al
    Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer-A Narrative Review.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available


    Cell Death Discov

  19. SUN J, Ma X, Ying Y, Wang W, et al
    SMAD3 and FTO are involved in miR-5581-3p-mediated inhibition of cell migration and proliferation in bladder cancer.
    Cell Death Discov. 2022;8:199.
    PubMed         Abstract available


    Cells

  20. UNGARO A, Tucci M, Audisio A, Di Prima L, et al
    Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
    Cells. 2022;11.
    PubMed         Abstract available


    Clin Cancer Res

  21. GIRARDI DM, Niglio SA, Mortazavi A, Nadal R, et al
    Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
    Clin Cancer Res. 2022;28:1353-1362.
    PubMed         Abstract available


    Clin Genitourin Cancer

  22. KOSIBA M, Stolzenbach LF, Colla Ruvolo C, Nocera L, et al
    Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder.
    Clin Genitourin Cancer. 2022;20:195.
    PubMed         Abstract available

  23. GRIVAS P, Huber C, Pawar V, Roach M, et al
    Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies.
    Clin Genitourin Cancer. 2022;20:114-122.
    PubMed         Abstract available

  24. DIAMANTOPOULOS LN, Korentzelos D, Alevizakos M, Wright JL, et al
    Sarcomatoid Urothelial Carcinoma: A Population-Based Study of Clinicopathologic Characteristics and Survival Outcomes.
    Clin Genitourin Cancer. 2022;20:139-147.
    PubMed         Abstract available

  25. TALUKDER R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, et al
    Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
    Clin Genitourin Cancer. 2022;20:165-175.
    PubMed         Abstract available

  26. LAYMON M, Mosbah A, Hashem A, Mahmoud O, et al
    Oncologic Outcomes of Squamous Cell Carcinoma Versus Urothelial Carcinoma With Squamous Differentiation After Radical Cystectomy for Bladder Carcinoma.
    Clin Genitourin Cancer. 2022;20:148-154.
    PubMed         Abstract available

  27. RAGGI D, Giannatempo P, Marandino L, Pierantoni F, et al
    Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.
    Clin Genitourin Cancer. 2022;20:155-164.
    PubMed         Abstract available

  28. MIYAKE M, Shimizu T, Nishimura N, Kiba K, et al
    Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
    Clin Genitourin Cancer. 2022;20:196.
    PubMed         Abstract available

  29. ABUHELWA AY, Bellmunt J, Kichenadasse G, McKinnon RA, et al
    Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy.
    Clin Genitourin Cancer. 2022;20:132-138.
    PubMed         Abstract available

  30. JINDAL T, Chou J, Friedlander T, Barata PC, et al
    Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series.
    Clin Genitourin Cancer. 2022;20:189-194.
    PubMed         Abstract available

  31. DEL GIUDICE F, van Uem S, Li S, Vilson FL, et al
    Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and
    Clin Genitourin Cancer. 2022;20:198.
    PubMed         Abstract available

  32. ADIBI M, McCormick B, Economides MP, Petros F, et al
    Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma.
    Clin Genitourin Cancer. 2022;20:176-182.
    PubMed         Abstract available

  33. FERRO M, Chiujdea S, Musi G, Lucarelli G, et al
    Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis.
    Clin Genitourin Cancer. 2022;20:e166-e172.
    PubMed         Abstract available

  34. TANG CH, Chen YC, Hsieh WT, Sue YM, et al
    Gender and Age Differences of Genitourinary Cancers Among Chronic Dialysis Patients in Taiwan.
    Clin Genitourin Cancer. 2022;20:e126-e134.
    PubMed         Abstract available


    Clin Nutr

  35. AL-ZALABANI AH, Wesselius A, Yi-Wen Yu E, van den Brandt P, et al
    Tea consumption and risk of bladder cancer in the Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) Study: Pooled analysis of 12 international cohort studies.
    Clin Nutr. 2022;41:1122-1130.
    PubMed         Abstract available


    Cureus

  36. ABDULLAH O, Parashar D, Mustafa IJ, Young AM, et al
    Venous Thromboembolism Rate in Patients With Bladder Cancer According to the Type of Treatment: A Systematic Review.
    Cureus. 2022;14:e22945.
    PubMed         Abstract available


    Curr Oncol

  37. VOUTSADAKIS IA
    Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
    Curr Oncol. 2022;29:1390-1407.
    PubMed         Abstract available


    Curr Treat Options Oncol

  38. HASHIMOTO H, Tanaka Y, Murata M, Ito T, et al
    Nectin-4: a Novel Therapeutic Target for Skin Cancers.
    Curr Treat Options Oncol. 2022;23:578-593.
    PubMed         Abstract available


    Drugs Aging

  39. RUSSELL BM, Boussi L, Bellmunt J
    Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?
    Drugs Aging. 2022;39:271-284.
    PubMed         Abstract available


    Eur Urol Focus

  40. DELL'OGLIO P, Turri F, Larcher A, D'Hondt F, et al
    Definition of a Structured Training Curriculum for Robot-assisted Radical Cystectomy with Intracorporeal Ileal Conduit in Male Patients: A Delphi Consensus Study Led by the ERUS Educational Board.
    Eur Urol Focus. 2022;8:160-164.
    PubMed         Abstract available

  41. MALDE S, Grover S, Raj S, Yuan C, et al
    A Systematic Review of the Efficacy and Safety of Outpatient Bladder Tumour Ablation.
    Eur Urol Focus. 2022;8:141-151.
    PubMed         Abstract available

  42. DEUKER M, Stolzenbach LF, Colla Ruvolo C, Nocera L, et al
    Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based Study.
    Eur Urol Focus. 2021;7:1332-1338.
    PubMed         Abstract available

  43. PANG KH, Thomas F, Novara G, Din OS, et al
    The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre.
    Eur Urol Focus. 2021;7:554-565.
    PubMed         Abstract available

  44. FURRER MA, Kiss B, Wuthrich PY, Thomas BC, et al
    Long-term Outcomes of Cystectomy and Crossfolded Ileal Reservoir Combined with an Afferent Tubular Segment for Heterotopic Continent Urinary Diversion: A Longitudinal Single-centre Study.
    Eur Urol Focus. 2021;7:629-637.
    PubMed         Abstract available

  45. NECCHI A, Madison R, Pal SK, Ross JS, et al
    Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Eur Urol Focus. 2021;7:1339-1346.
    PubMed         Abstract available

  46. MASTROIANNI R, Brassetti A, Krajewski W, Zdrojowy R, et al
    Assessing the Impact of the Absence of Detrusor Muscle in Ta Low-grade Urothelial Carcinoma of the Bladder on Recurrence-free Survival.
    Eur Urol Focus. 2021;7:1324-1331.
    PubMed         Abstract available

  47. TURAL D, Olmez OF, Sumbul AT, Artac M, et al
    Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
    Eur Urol Focus. 2021;7:1061-1066.
    PubMed         Abstract available

  48. SEISEN T, Mari A, Campi R, Peyronnet B, et al
    Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review.
    Eur Urol Focus. 2021;7:1075-1083.
    PubMed         Abstract available


    Eur Urol Oncol

  49. WARD DG, Baxter L, Ott S, Gordon NS, et al
    Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA.
    Eur Urol Oncol. 2022 Apr 8. pii: S2588-9311(22)00036.
    PubMed         Abstract available


    Expert Rev Anticancer Ther

  50. MATHEW THOMAS V, Tripathi N, Agarwal N, Swami U, et al
    Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
    Expert Rev Anticancer Ther. 2022;22:335-341.
    PubMed         Abstract available


    Front Genet

  51. WANG F, Dong X, Yang F, Xing N, et al
    Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.
    Front Genet. 2022;13:831146.
    PubMed         Abstract available


    Front Immunol

  52. XIA QD, Sun JX, Xun Y, Xiao J, et al
    SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer.
    Front Immunol. 2022;13:864156.
    PubMed         Abstract available


    Funct Integr Genomics

  53. MAO C, Gao Y, Wan M, Xu N, et al
    Identification of glycolysis-associated long non-coding RNA regulatory subtypes and construction of prognostic signatures by transcriptomics for bladder cancer.
    Funct Integr Genomics. 2022 Apr 14. pii: 10.1007/s10142-022-00845.
    PubMed         Abstract available


    Int J Environ Res Public Health

  54. DAUBISSE-MARLIAC L, Grosclaude P, Carulla M, Parada D, et al
    Registration of Urothelial Tumours in Cancer Registries: How to Improve and Make It More Useful?
    Int J Environ Res Public Health. 2022;19.
    PubMed         Abstract available


    Int J Mol Sci

  55. XU L, Su B, Mo L, Zhao C, et al
    Norcantharidin Induces Immunogenic Cell Death of Bladder Cancer Cells through Promoting Autophagy in Acidic Culture.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available


    Int J Nanomedicine

  56. QIAN H, Wang Y, Ma Z, Qian L, et al
    Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy.
    Int J Nanomedicine. 2022;17:1635-1646.
    PubMed         Abstract available


    Int J Surg Pathol

  57. MONTOYA-CERRILLO D, Briski LM, Jorda M, Kryvenko ON, et al
    Utility of GATA-3 and Cytokeratin 5/6 Immunostains in Separating Condyloma Acuminatum Arising in the Urinary Tract From Non-Invasive Papillary Urothelial Carcinoma.
    Int J Surg Pathol. 2022;30:260-264.
    PubMed         Abstract available


    J Clin Lab Anal

  58. LI X, Zhou L, Lu T, Zhang L, et al
    Constructing an immune- and ferroptosis-related lncRNA signature to predict the immune landscape of human bladder cancer.
    J Clin Lab Anal. 2022 Apr 14:e24389. doi: 10.1002/jcla.24389.
    PubMed         Abstract available


    J Nephrol

  59. YILDIRIM S, Ozkan EI, Sadioglu A, Gonul II, et al
    Bone in bladder.
    J Nephrol. 2022;35:1043-1044.
    PubMed        


    J Osteopath Med

  60. WILSON J, Drach D, Zanghi J, Siegert J, et al
    Improving practice patterns in patients with newly diagnosed bladder masses treated with transurethral resection.
    J Osteopath Med. 2022;122:169-173.
    PubMed         Abstract available


    J Urol

  61. MASTROIANNI R, Ferriero M, Tuderti G, Anceschi U, et al
    Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial.
    J Urol. 2022;207:982-992.
    PubMed         Abstract available


    Lancet Oncol

  62. HUSSAIN SA, Lester JF, Jackson R, Gornall M, et al
    Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
    Lancet Oncol. 2022 Apr 11. pii: S1470-2045(22)00158.
    PubMed         Abstract available


    Nat Commun

  63. NIKOLOS F, Hayashi K, Hoi XP, Alonzo ME, et al
    Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors.
    Nat Commun. 2022;13:1487.
    PubMed         Abstract available

  64. HOLM JS, Funt SA, Borch A, Munk KK, et al
    Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
    Nat Commun. 2022;13:1935.
    PubMed         Abstract available


    PLoS One

  65. ISONO M, Okubo K, Asano T, Sato A, et al
    Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
    PLoS One. 2022;17:e0266476.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  66. SUN X, Xie L, Qiu S, Li H, et al
    Elucidation of CKAP4-remodeled cell mechanics in driving metastasis of bladder cancer through aptamer-based target discovery.
    Proc Natl Acad Sci U S A. 2022;119:e2110500119.
    PubMed         Abstract available


    Sci Rep

  67. LIN N, Chen L, Zhang Y, Yang Y, et al
    KIF4A promotes tumor progression of bladder cancer via CXCL5 dependent myeloid-derived suppressor cells recruitment.
    Sci Rep. 2022;12:6015.
    PubMed         Abstract available


    Transl Androl Urol

  68. MA Q, Xu C, Han X, Wang X, et al
    The effects of modified RNA-binding proteins HuR on the biological behavior of the bladder cancer T24 cell line.
    Transl Androl Urol. 2022;11:348-357.
    PubMed         Abstract available

  69. LIU F, Liu X, Deng W, Yang X, et al
    Overexpression of F-box and WD repeat domain containing 7 prevents tumor growth of bladder cancer cells through regulating SREBP1a.
    Transl Androl Urol. 2022;11:367-376.
    PubMed         Abstract available


    Urol Oncol

  70. LI YD, Gao L, Gou YQ, Tan W, et al
    Age of menarche and primary bladder cancer risk: A meta-analysis and systematic review.
    Urol Oncol. 2022 Apr 7. pii: S1078-1439(22)00074.
    PubMed         Abstract available

  71. SHARMA G, Sharma A, Krishna M, Ahluwalia P, et al
    Diagnostic performance of minichromosome maintenance 5 (MCM5) in bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2022 Apr 9. pii: S1078-1439(22)00075.
    PubMed         Abstract available


    Virchows Arch

  72. KOBAYASHI G, Hayashi T, Sentani K, Babasaki T, et al
    Clinicopathological significance of claspin overexpression and its efficacy as a novel biomarker for the diagnosis of urothelial carcinoma.
    Virchows Arch. 2022;480:621-633.
    PubMed         Abstract available


    World J Urol

  73. REESINK DJ, van de Garde EMW, van der Nat P, Somford DM, et al
    Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands.
    World J Urol. 2022 Apr 10. pii: 10.1007/s00345-022-03987.
    PubMed         Abstract available

  74. SPARWASSER P, Epple S, Thomas A, Dotzauer R, et al
    First completely robot-assisted retroperitoneal nephroureterectomy with bladder cuff: a step-by-step technique.
    World J Urol. 2022;40:1019-1026.
    PubMed         Abstract available

  75. KARAM A, Mjaess G, Albisinni S, El Daccache Y, et al
    Uncovering the role of urinary microbiota in urological tumors: a systematic review of literature.
    World J Urol. 2022;40:951-964.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: